7 September 2016
Markers associated with Alzheimer’s and Parkinson’s diseases are present in Mexico City children chronically exposed to concentrations of fine particulate matter PM2.5 above the current EPA USA standards
A new study by researchers at the Universities of Montana, Valle de México, Boise State, Veracruz University, Médica Sur, Centro de Ciencias de la Atmósfera, UNAM, Hospital Regional de Alta Especialidad, Ciudad Victoria, Hospital de Especialidades #14, IMSS, Centre Hospitalier Universitaire, Hôpital de Hautepierre and AJ Roboscreen GmbH heightens concerns over the detrimental impact of fine particulate matter PM2.5 on CSF markers associated with Alzheimer and Parkinson’s diseases in children ages 11.9±4.8 years. These findings are published in the Journal of Alzheimer’s Disease.
2 September 2016
Subjective Cognitive Decline and risk of future AD dementia - results from a German multi-center study highlights the importance of temporal consistency
A new study, based on longitudinal data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe), suggests that temporal stability versus instability of an individual’s report of subjective worsening of cognition over time plays an important role with regard to whether such experiences are associated with future dementia risk. These findings, which will be published in the Journal of Alzheimer's Disease 54(3), add to a constantly growing strand of research on the phenomenon of “Subjective Cognitive Decline” (SCD) in Alzheimer’s Disease (AD).
29 August 2016
To keep our JAD editors, authors, and readers informed of JAD's progress and development, the journal hereby shares the 2016 editorial update. View the full presentation, which includes highlights such as the best-viewed papers of 2015, the most popular press releases, and interesting journal statistics such as the improved turn-around times and submission rates.
10 August 2016
A new study, based on data from the Framingham Heart Study (FHS) suggests a simple test of physical functioning may be able to help physicians identify individuals who are at a higher risk for developing Alzheimer’s disease and stroke. These findings, which appear in the Journal of Alzheimer’s Disease, provide hope that there are easy-to-test clinical markers that will help physicians identify individuals who are at increased risk for common age-related neurological diseases.
27 July 2016
A new study by researchers at Neuroscience Research Australia (NeuRA) has identified the emergence of positive changes that occur after a person has been diagnosed with dementia. The first of its kind, the study has confirmed anecdotal evidence that creative skills such as painting, drawing, or singing – which were not previously evident in an individual – can emerge or improve in people with Alzheimer’s disease and frontotemporal dementia.
20 July 2016
New findings published today by a team of researchers led by Dr. Andres Lozano at the Krembil Neuroscience Centre (KNC) of Toronto Western Hospital (TWH) have provided further insight into the effects of Deep Brain Stimulation (DBS) in the treatment of Alzheimer’s disease.
14 July 2016
The Journal of Alzheimer’s Disease (JAD) is pleased to announce that Mark W. Bondi has been chosen as the recipient of the 2016 Alzheimer Award presented by the journal in recognition of his outstanding work on the development of a novel and promising method of staging preclinical Alzheimer’s disease (AD) based on number of abnormal biomarkers that is predictive of progression to mild cognitive impairment (MCI) and AD.
12 July 2016
Can estrogen preserve brain function and decrease the risk of Alzheimer’s disease when given early in menopause? Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer’s disease, a Mayo Clinic study published this month in the Journal of Alzheimer’s Disease found. Ultimately, these deposits harm neurons, leading to cognitive problems.
12 July 2016
No single assessment tool is able to consistently determine driving ability in people with Alzheimer’s disease and mild cognitive impairment, a St. Michael’s Hospital research review has found. Individuals with very mild and mild Alzheimer’s disease who took a road test had a failure rate of 13.6 and 33.3 per cent respectively, compared to a failure rate of 1.6 per cent in drivers without Alzheimer’s disease. However, in general, patients with any degree of Alzheimer’s disease still had a pass rate of almost more than 46 per cent. The comprehensive research review, published today in the Journal of Alzheimer’s Disease, found largely inconsistent results across 32 studies that looked at various cognitive tests in conjunction with driving outcomes, on-road evaluations and driving simulations.
23 May 2016
Mild cognitive impairment (MCI) is a slight but noticeable and measurable decline in cognitive abilities, such as remembering names or a list of items. While changes may not be severe enough to disrupt daily life, a clinical diagnosis of MCI indicates an increased risk of eventually developing Alzheimer’s disease or another type of dementia.